# Dizal Pharmaceuticals clinical trials: 39 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 39 trials with Dizal Pharmaceuticals as lead sponsor, 15 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Dizal Pharmaceuticals: 39 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/dizal-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 39
- Recruiting or not yet: 15
- Read on: November 19, 2026

## Trials

The 25 newest of 39, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07888569 | Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21) | Dizal Pharmaceuticals | Phase 1 | Recruiting | Healthy | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888569) |
| July 17, 2026 | NCT07712588 | Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) | Dizal Pharmaceuticals | Phase 2/3 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712588) |
| March 27, 2026 | NCT07496229 | Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) | Dizal Pharmaceuticals | Phase 1/2 | Recruiting | T-cell Lymphomas | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07496229) |
| March 6, 2026 | NCT07454863 | A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15) | Dizal Pharmaceuticals | Phase 1 | Completed | Lymphoma, Non-Hodgkin | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454863) |
| January 9, 2026 | NCT07328217 | A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors | Dizal Pharmaceuticals | Phase 1/2 | Recruiting | Advanced Solid Tumors | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328217) |
| December 19, 2025 | NCT07294365 | A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) | Dizal Pharmaceuticals | Phase 2 | Recruiting | Immune Thrombocytopenia (ITP) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294365) |
| November 18, 2025 | NCT07234162 | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) | Dizal Pharmaceuticals | Phase 3 | Recruiting | Peripheral T-cell Lymphoma | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234162) |
| September 4, 2025 | NCT07154264 | A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) | Dizal Pharmaceuticals | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07154264) |
| August 24, 2025 | NCT07139873 | A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) | Dizal Pharmaceuticals | Phase 3 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07139873) |
| July 23, 2025 | NCT07079475 | Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) | Dizal Pharmaceuticals | Phase 1/2 | Recruiting | Non-Small Cell Lung Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07079475) |
| July 17, 2025 | NCT07070440 | DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) | Dizal Pharmaceuticals | Phase 1/2 | Recruiting | Non Small Cell Lung Cancer | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070440) |
| July 11, 2025 | NCT07059650 | DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) | Dizal Pharmaceuticals | Phase 1/2 | Recruiting | Diffuse Large B-Cell Lymphoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07059650) |
| April 1, 2025 | NCT06905197 | A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1) | Dizal Pharmaceuticals | Phase 1 | Recruiting | Non Small Cell Lung Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06905197) |
| February 6, 2025 | NCT06813365 | Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2) | Dizal Pharmaceuticals | Phase 1 | Recruiting | Nonsmall-cell Lung Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06813365) |
| August 6, 2024 | NCT06539195 | DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) | Dizal Pharmaceuticals | Phase 2 | Completed | Diffuse Large B Cell Lymphoma | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06539195) |
| August 6, 2024 | NCT06539182 | DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) | Dizal Pharmaceuticals | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06539182) |
| July 22, 2024 | NCT06511895 | AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) | Dizal Pharmaceuticals | Phase 2 | Completed | Peripheral T Cell Lymphoma | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06511895) |
| July 22, 2024 | NCT06511869 | AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) | Dizal Pharmaceuticals | Phase 2 | Completed | Peripheral T-cell Lymphoma | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06511869) |
| March 6, 2024 | NCT06295432 | A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) | Dizal Pharmaceuticals | Phase 2 | Completed | Non-small Cell Lung Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06295432) |
| February 23, 2024 | NCT06276283 | DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) | Dizal Pharmaceuticals | Phase 2 | Recruiting | Non-small Cell Lung Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06276283) |
| October 16, 2023 | NCT06084104 | DZD9008 PK Study in Hepatic Impairment Subjects | Dizal Pharmaceuticals | Phase 1 | Completed | Hepatic Impairment | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06084104) |
| July 3, 2023 | NCT05926180 | Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in... | Dizal Pharmaceuticals | Phase 1 | Completed | Non-small Cell Lung Cancer | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05926180) |
| May 6, 2023 | NCT05844956 | A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) | Dizal Pharmaceuticals | Phase 1/2 | Completed | Lymphoma, Non-Hodgkin | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05844956) |
| April 21, 2023 | NCT05824585 | DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Dizal Pharmaceuticals | Phase 1 | Completed | Lymphoma, Non-Hodgkin | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05824585) |
| February 6, 2023 | NCT05712902 | Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) | Dizal Pharmaceuticals | Phase 2 | Active not recruiting | Non-Small Cell Lung Cancer | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05712902) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 16 |
| Phase 1/2 | 10 |
| Phase 2 | 9 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Recruiting | 14 |
| Active not recruiting | 3 |
| Terminated | 1 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 11 |
| Lymphoma, T-Cell, Peripheral | 4 |
| Lymphoma, Non-Hodgkin | 3 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 |
| Lymphoma, Large B-Cell, Diffuse | 3 |
| Recurrence | 1 |
| Lymphoma, T-Cell | 1 |
| Purpura, Thrombocytopenic, Idiopathic | 1 |
| Lung Neoplasms | 1 |
| Lymphoma, B-Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Nigerian restaurants in the United States](https://specstream.ai/data/businesses/nigerian-restaurants/united-states)
- [Prenatal and perinatal care clinics in the United States](https://specstream.ai/data/businesses/prenatal-and-perinatal-care-clinics/united-states)
- [Shipping and delivery companies in the United States](https://specstream.ai/data/businesses/shipping-and-delivery-companies/united-states)
- [Trailer repair shops in the United States](https://specstream.ai/data/businesses/trailer-repair-shops/united-states)
- [African restaurants in the United States](https://specstream.ai/data/businesses/african-restaurants/united-states)
